Fenofibrate Colon-Targeted Nanosponges Development, Optimization, and In-Vivo Anti-Inflammatory Efficacy of Fenofibrate Nanosponges: A Box–Behnken Design Approach to Formulation, Pharmacokinetics, and Experimental Colitis
Background: Fenofibrate, a PPAR-α agonist with anti-inflammatory, lipid-modulating and lipid-lowering properties, is limited clinically by poor aqueous solubility and low oral bioavailability, restricting its use for inflammatory bowel disease (IBD). This study aimed to develop and optimize fenofibrate nanosponge formu...